INBX Inhibrx Biosciences, Inc.

bullish · high conviction track record → $110.01 +0.50 (+0.5%)
Mkt Cap $2B 52wk $12.03 - $155.29 14d ago
Insider buying: $11,340,621 bought by 7 insiders (30d)
Est. revisions: +0.0%
Backed by structured data (insider trades, analyst ratings, or filings)
Factor Model (net +0.5)

Factor Model

net +0.5 1.0 / 10
Est. Revisions
+0.0
Insider Activity
+0.5
Momentum
+0.0
Analyst Rev.
+0.0
Narrative Gap
+0.5

Inhibrx insiders buy $7.5M, study results boost

Watch: Next clinical trial updates and FDA milestones to confirm therapeutic potential and support the $300 target.

Inhibrx insiders purchased over $7.5 million of stock across multiple transactions, including large buys by KAYYEM JON FAIZ and FORSYTH DOUGLAS at prices ranging from $12.89 to $18.24. The Phase 2 HexAgon study showed a 44% objective response rate in combination with pembrolizumab for head and neck cancer, with some patients achieving complete tumor remission. Stifel raised the price target to $300 while maintaining a buy rating.

Strong insider buying paired with positive trial data and a doubled Stifel target underlines robust confidence in Inhibrx's lead candidate and potential valuation upside.

Evidence

15d ago Insider buy by KAYYEM JON FAIZ (INBX): $4,927,580
15d ago Insider buy by KAYYEM JON FAIZ (INBX): $997,024
15d ago Insider buy by LAPPE MARK (INBX): $518,282
15d ago Insider buy by FORSYTH DOUGLAS (INBX): $1,037,328
15d ago Insider buy by MANHARD KIMBERLY J (INBX): $139,800
15d ago Insider buy by VUORI KRISTIINA S. (INBX): $99,960
15d ago Insider buy by LAPPE MARK (INBX): $671,150
15d ago Insider buy by VUORI KRISTIINA S. (INBX): $99,992
6 older signals
15d ago Insider buy by LAPPE MARK (INBX): $629,117
15d ago Insider buy by VUORI KRISTIINA S. (INBX): $100,005
15d ago Insider buy by KAYYEM JON FAIZ (INBX): $1,523,620
15d ago Insider sell by VIKING GLOBAL INVESTORS LP (INBX): $11,287,500
15d ago Insider buy by LAPPE MARK (INBX): $596,763
16d ago Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study
Fundamentals & Data ▾
Inhibrx Biosciences, Inc. Healthcare · Biotechnology
Mkt Cap
$2B
52w Range
$12.03 - $155.29
Short Interest
2.7M 25.05%
Days to Cover
5.8 +29%
Technicals downtrend
from 52w Hi
-18.1%
1w return
-6.7%
Insiders
buying 11B / 1S
EPS Estimate
$-1.34 +0.0% 30d 0up / 0dn
Est. Dispersion
0% 1 analysts
Analyst Target
$278 $230 - $325
Options P/C
0.08
Insider Cluster
strong buy 5B / 1S (officer)
Fund Convergence
strong Elliott, Citadel, Renaissance, D.E. Shaw
Top Holders
Elliott $114M
Citadel $16M
Renaissance $3M
D.E. Shaw $2M
Recent Filings & Data
insider trade 21
net buying · $11,287,500 sold · $11,340,621 bought
7 insiders · 21 transactions (30d)
Recent transactions
VIKING GLOBAL INVESTORS LP · sell · $11,287,500
KAYYEM JON FAIZ · other
KAYYEM JON FAIZ · other
KAYYEM JON FAIZ · other
KAYYEM JON FAIZ · buy · $1,523,620
VUORI KRISTIINA S. · buy · $100,005
LAPPE MARK · buy · $629,117
VUORI KRISTIINA S. · buy · $99,992
LAPPE MARK · buy · $671,150
LAPPE MARK · buy · $596,763
VUORI KRISTIINA S. · buy · $99,960
MANHARD KIMBERLY J · buy · $139,800
FORSYTH DOUGLAS · buy · $1,037,328
LAPPE MARK · buy · $518,282
KAYYEM JON FAIZ · other
KAYYEM JON FAIZ · buy · $997,024
KAYYEM JON FAIZ · buy · $4,927,580
LAPPE MARK · award
FORSYTH DOUGLAS · award
KAYYEM JON FAIZ · award
ECKELMAN BRENDAN P · award
14 signals · latest 15d ago

Keep reading the market

Direction shifts, insider clusters, filing red flags, and earnings call changes stay published on the site.

All stocks → Track record → How it works →